Duopharma Biotech Berhad (KLSE:DPHARMA)
Malaysia · Delayed Price · Currency is MYR 1.230
0.00 (0.00%)
At close: Aug 10, 2026
Duopharma Biotech Berhad Ratios and Metrics
Market cap in millions MYR. Fiscal year is January - December.
Millions MYR. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,183 | 1,202 | 1,202 | 1,212 | 1,533 | 1,582 | |
Market Cap Growth | -4.65% | 0% | -0.79% | -20.94% | -3.10% | -33.70% |
Enterprise Value | 1,397 | 1,428 | 1,469 | 1,522 | 1,819 | 1,881 |
Last Close Price | 1.23 | 1.22 | 1.19 | 1.17 | 1.47 | 1.51 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 12.80 | 13.75 | 19.19 | 23.02 | 21.87 | 24.09 |
Forward PE | 11.76 | 12.08 | 14.74 | 14.77 | 15.91 | 20.97 |
PS Ratio | 1.29 | 1.29 | 1.48 | 1.72 | 2.20 | 2.48 |
PB Ratio | 1.56 | 1.59 | 1.70 | 1.76 | 2.34 | 2.54 |
P/TBV Ratio | 1.64 | 1.60 | 1.71 | 1.78 | 2.35 | 2.56 |
P/FCF Ratio | 16.02 | 15.03 | 20.12 | 76.43 | 301.61 | - |
P/OCF Ratio | 11.94 | 11.26 | 14.43 | 24.84 | 21.82 | 36.62 |
PEG Ratio | 0.97 | 0.61 | 0.72 | 12.31 | 1.10 | 4.11 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.52 | 1.53 | 1.81 | 2.16 | 2.61 | 2.94 |
EV/EBITDA Ratio | 7.76 | 8.35 | 10.70 | 13.35 | 14.80 | 16.36 |
EV/EBIT Ratio | 10.01 | 10.67 | 14.66 | 19.34 | 19.57 | 21.19 |
EV/FCF Ratio | 18.91 | 17.85 | 24.59 | 95.99 | 357.77 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.64 | 0.66 | 0.73 | 0.80 | 0.66 | 0.65 |
Debt / EBITDA Ratio | 2.69 | 2.84 | 3.66 | 4.67 | 3.41 | 3.41 |
Debt / FCF Ratio | 6.56 | 6.20 | 8.63 | 34.61 | 84.91 | - |
Net Debt / Equity Ratio | 0.28 | 0.27 | 0.35 | 0.41 | 0.42 | 0.43 |
Net Debt / EBITDA Ratio | 1.21 | 1.20 | 1.83 | 2.44 | 2.23 | 2.31 |
Net Debt / FCF Ratio | 2.90 | 2.57 | 4.20 | 17.55 | 53.90 | -4.02 |
Asset Turnover | 0.64 | 0.66 | 0.60 | 0.55 | 0.58 | 0.57 |
Inventory Turnover | 2.03 | 2.10 | 2.08 | 1.83 | 1.82 | 2.06 |
Quick Ratio | 1.68 | 1.66 | 2.65 | 2.59 | 1.13 | 1.18 |
Current Ratio | 2.62 | 2.60 | 4.08 | 4.06 | 2.05 | 2.15 |
Return on Equity (ROE) | 12.60% | 11.93% | 8.97% | 7.84% | 10.96% | 10.36% |
Return on Assets (ROA) | 6.13% | 5.91% | 4.60% | 3.83% | 4.87% | 4.99% |
Return on Invested Capital (ROIC) | 10.99% | 10.59% | 8.15% | 6.91% | 8.44% | 8.37% |
Return on Capital Employed (ROCE) | 12.30% | 11.80% | 8.40% | 6.70% | 9.70% | 9.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 7.82% | 7.27% | 5.21% | 4.34% | 4.57% | 4.15% |
FCF Yield | 6.24% | 6.65% | 4.97% | 1.31% | 0.33% | -4.18% |
Dividend Yield | 3.70% | 3.72% | 2.52% | 1.96% | 1.56% | 1.44% |
Payout Ratio | 47.33% | 38.49% | 42.99% | 16.81% | 11.70% | 68.45% |
Buyback Yield / Dilution | -0.06% | - | -0.36% | -1.08% | -2.15% | -0.02% |
Total Shareholder Return | 3.64% | 3.72% | 2.16% | 0.89% | -0.59% | 1.42% |